Protocolo de tratamiento antibiótico de las osteomielitis

  1. Barbero Allende, J.M. 1
  2. García Sánchez, M. 1
  3. Arranz Caso, A. 1
  1. 1 Servicio de Medicina Interna. Hospital Universitario Príncipe de Asturias. Universidad de Alcalá de Henares. Alcalá de Henares. Madrid. España
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2022

Titel der Ausgabe: Enfermedades infecciosas (IV)

Serie: 13

Nummer: 52

Seiten: 3072-3075

Art: Artikel

DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Zusammenfassung

Osteomyelitis is an infectious disease that is difficult to treat and on which there is little scientific evidence. It can be caused by various pathogenic mechanisms and multiple microorganisms. The most commonly involved microorganism is Staphylococcus aureus. Correct identification of the causative agent is essential for guaranteeing the best treatment and, on many occasions, surgical debridement of the affected bone and adjacent tissues is necessary. In general, antibiotics disseminate worse in the bone than in other tissues. Therefore, higher doses and longer treatment durations are needed. Antibiotics that better penetrate this tissue are preferred. There is now sufficient evidence to affirm that shorter treatments with a shorter duration of parenteral administration than what is classically recommended are equally efficacious.

Bibliographische Referenzen

  • Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364:369-79.
  • Mensa J, Soriano A, López Suñe E, Llinares P, Zboromyrska Y, Barberán J. Osteomielitis. En: Mensa J, Soriano A, López-Suñe E, Llinares P, Zboromyrska Y, Barberán J, eds. Guía de terapéutica antimicrobiana 2021. Barcelona: Antares; 2021. p. 817-21.
  • Osmon D. Nonvertrebral osteomyelitis in adults: Treatment. En: Spelman D, ed. UpToDate 2021.
  • Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380: 425-36.
  • Benavent E, Morata L, Escrihuela Vidal F, Reynaga EA, Soldevila L, Albiach L. Long-term use of tedizolid in osteoarticular infections: Benefits among oxazolidinone drugs. Antibiotics (Basel). 2021;10:53
  • Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylo- coccal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279(19):1537-41.
  • Morata L, Senneville E, Bernard L, Nguyen S, Buzelé R, Druon J. A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention. Infect Dis Ther. 2014;3:235-43.
  • Euba G, Murillo O, Fernández Sabé N, Mascaró J, Cabo J, Pérez A. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother. 2009; 53:2672-6.
  • Wilson BM, Bessesen MT, Doros G, Brown ST, Saade E, Hermos J. Adjunctive rifampin therapy for diabetic foot osteomye- litis in the veterans health administration. JAMA Netw Open. 2019; 2(11): e1916003.
  • Morata L, Cobo J, Fernández Sampedro M, Guisado Vasco P, Ruano E, Lora Tamayo J. Safety and efficacy of prolonged use of dalbavanci in bone and joint infections. Antimicrob Agents Chemother. 2019;63: e02280-18.
  • Laghmouche N, Compain F, Jannot AS, Guigui P, Mainardi JL, Lonjon G. Successful treatment of Pseudomonas aeruginosa osteomyelitis with antibiotic monotherapy of limited duration. J Infect. 2017;75:198-206.
  • Euba G, Lora Tamayo J, Murillo O, Pedrero S, Cabo J, Verdaguer R. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother. 2009;53(10):4305-10.
  • Huang CY, Hsieh RW, Yen HT, Hsu TC, Chen CY, Chen YC. Short- versus long-course antibiotics in osteomyelitis: A systematic review and meta-analysis. Int J Antimicrob Agents. 2019; 53:246-60.
  • Benkabouche M, Racloz G, Spechbach H, Lipsky B, Gaspoz JM, Uçkay I. Four versus six weeks of antibiotic therapy for osteoarticular infections after implant removal: a randomized trial. J Antimicrob Chemother. 2019;74:2394-9.
Fuente de los datos: Dialnet